chronic hepatitis b is still a major public health issue despite the successful prophylactic vaccination attempts. chronicity of hepatitis b virus(hbv) is mainly due to its ability to debilitate host's immune system. therefore, major measures have been taken to stop this process and help patients with chronic hepatitis b infection recover from their illness. while satisfactory results have...

BACKGROUND It is known that the immunogenicity of hepatitis B virus (HBV) vaccine is lower in uremic patients than healthy subjects. Numerous inherited or acquired factors have been implicated in this lowered response, and the high frequency of recombinant human erythropoietin use among patients on maintenance dialysis has been suggested to play a pivotal role. However, the impact of therapy wi...

we read with a great interest the article written by davoodbeglou and colleagues entitled “evaluation of hepatitis b infection prevalence in institutionalized intellectually disabled children” which is recently published in your prestigious journal 1 . the authors concluded that hbv infection is more prevalent among institutionalized disabled children and that we should change our health polici...

Background and Aims: Viral hepatitis is a global health problem with a high mortality rate. Recently, a new Flavi-like virus, provisionally named hepatitis G virus (HGV), has been described. HGV does not induce an immune response that is consistently detectable by using recombinant proteins from prokaryotic expression, therefore studies have been conducted by using polymerase chain reaction (...

Hepatitis C virus (HCV) infection is highly prevalent in thalassemic patients, and this may decrease the serum antibody response to hepatitis B virus (HBV) vaccine. There is also some alteration of the immune system in multi-transfused thalassemic patients, as a consequence of iron overload. We investigated whether HCY infection may reduce the effectiveness of HBY vaccine in multi - transf...

BACKGROUND A therapeutic vaccine for chronic hepatitis B virus (HBV) infection that enhances virus-specific cellular immune responses is urgently needed. The "prime-boost" regimen is a widely used vaccine strategy against many persistence infections. However, few reports have addressed this strategy applying for HBV therapeutic vaccine development. METHODOLOGY/PRINCIPAL FINDINGS To develop an...

conclusions dental academics were unsure about the means of infection and prevention against hbv. many of them had not completed the immunization scheme and did not have the test of seroconversion. the serological analysis revealed unprotection, even after students completed the vaccination schedule. results of the 179 students surveyed, 58.1% knew about the degree of virulence of the hepatitis...

background: hepatitis b virus (hbv) fails to produce appropriate immune responses in some healthy individuals; thus, different strategies have been adopted to promote immune responses. the current study aimed at evaluating the efficacy of hbv vaccine coadministered with tetanus-diphtheria (td) vaccine compared with hbv vaccine in healthy individuals through measuring hepatitis b surface antibod...

background: conventional hepatitis b virus (hbv) vaccination fails to achieve efficient protection in about 5–10% of the world population. hence, different strategies have been adopted to ameliorate hbv antibody titers. this study aimed to evaluate the concurrent application of tetanus‑diphtheria (td) and hbv vaccination on hepatitis b surface (hbs) antibody titer in low‑responder healthy indiv...

Reports of multiple sclerosis developing after hepatitis B vaccination have led to the concern that this vaccine might be a cause of multiple sclerosis in previously healthy subjects. Some articles evidenced that minor Hepatitis B virus (HBV) polymerase proteins could be produced by alternative transcriptional or translational strategies. Their detection is very difficult because they are in mi...